License Agreement - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 30, 2024	Apr. 30, 2019	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2019	Aug. 31, 2010
License Agreement [Line Items]
Annual minimum royalty obligations								$ 0.2
Immuno Gen Inc
License Agreement [Line Items]
Milestone payment	$ 5.0
Clinical Development Milestone Payment	35.0
Remaining potential development milestone payments	30.0
Immuno Gen Inc \| First Phase 2 Study
License Agreement [Line Items]
Remaining potential development milestone payments	10.0
Immuno Gen Inc \| First Phase 3 Study
License Agreement [Line Items]
Remaining potential development milestone payments	$ 20.0
Immuno Gen Inc \| Collaborative Arrangement
License Agreement [Line Items]
Upfront payment received							$ 7.5
Immuno Gen Inc \| Clinical development milestones \| Maximum
License Agreement [Line Items]
Milestone payment							35.0
Immuno Gen Inc \| Regulatory approval and commercial milestone \| Maximum
License Agreement [Line Items]
Milestone payment							$ 320.0
UCSB
License Agreement [Line Items]
License Payment Term One		2031-01
Annual license maintenance fee		$ 0.8
Percentage of remaining maintenance fees outstanding		50.00%
Sublicense fees			$ 0.0	$ 0.0	$ 0.9	$ 1.1